Article
Seagen's breast cancer therapy succeeds in late-stage study
Rating:
0.0
Views:
39
Likes:
1
Library:
1
Seagen said on Wednesday that a combination of its therapy, Tukysa, met the main goal of a late-stage study in some breast cancer patients, boosting the prospects of the company that is in the process of being acquired by Pfizer Inc .
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value